SCHEMBL7950810

SCHEMBL7950810

CC(c1cccc([N+](=O)[O-])c1)c1c[nH]c2ncc(-c3cccnc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.46
NEK1 Q96PY6 2/20 0.46
DYRK1A Q13627 4/20 0.44
NTRK1 P04629 1/20 0.44
PIK3CA P42336 1/20 0.44
KIT P10721 1/20 0.44
MET P08581 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
BCR P11274 1/20 0.43
SRC P12931 1/20 0.43
PRKCA P17252 1/20 0.43
CCNT1 O60563 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CDK9 P50750 1/20 0.42
CLK1 P49759 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3505643 0.89 RIPK1 (0.47) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL413620 0.89 NEK1 (0.47) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL856729 0.77 ALK (0.48) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL5447076 0.77 RIPK1 (0.46) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL856725 0.77 NEK1 (0.52) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL26873751 0.74 MET (0.57) METPDE4DSRCRAB9A
SCHEMBL413619 0.74 NEK1 (0.46) RIPK1NEK1DYRK1ANTRK1PIK3CA
SCHEMBL12663601 0.73 DYRK1A (0.52) NEK1DYRK1ANTRK1PIK3CAKIT
SCHEMBL26696380 0.73 MET (0.55) METSRCRAB9A
SCHEMBL878745 0.72 NEK1 (0.49) NEK1DYRK1ANTRK1PIK3CAKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415469-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2013-04-09 US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 US disclosed
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents PLEXXIKON INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents MAP4K1, MAP4K2, MAP3K1 RIPK1 473/4885NEK1 293/4885DYRK1A 646/4885
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 RIPK1 507/4885NEK1 223/4885DYRK1A 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.